-
Brazil patient groups challenge Conitec rules on civil society participation
Brasília – Patient organizations in Brazil are preparing legal action against current rules of the National Committee for Health Technology Incorporation (Conitec), arguing that recent regulations fail to ensure effective participation of civil society in decision-making on technology incorporation into the public health system. The initiative is led by Casa Hunter, which claims that restrictions…
-
Brazil to test lung cancer screening program in public health system
Brasília – The National Cancer Institute (INCA) announces a pilot study to evaluate the feasibility of implementing a lung cancer screening program within the Unified Health System (SUS). Conducted in partnership with the Rio de Janeiro municipal health authority and supported by AstraZeneca, the initiative aims to generate evidence for a future national guideline focused…
-
Brazil seen as priority market for Novo Nordisk’s oral Wegovy
Brasília – Novo Nordisk identifies Brazil as a priority market for the launch of its oral version of Wegovy, a semaglutide-based treatment for obesity, as the company seeks to expand its footprint in one of the world’s fastest-growing weight management markets. The tablet formulation, already submitted to the National Health Surveillance Agency (ANVISA), is expected…
-
Brazil’s CMED fines drug distributors and defends stricter regulation
Brasília – The Drug Market Regulation Chamber (CMED) imposes more than BRL 13.5 million in fines on pharmaceutical distributors for offering medicines above regulated price ceilings, reinforcing its stance on stricter market oversight. Sanctioned companies include Imediata Distribuidora de Produtos para a Saúde, Fabmed Distribuidora Hospitalar, Panorama Comércio de Produtos Médicos e Farmacêuticos, and Realmed…
-
Brazil’s Hemobrás expands investments to strengthen domestic production of hemoderivatives
Brasília – The Brazilian Company of Hemoderivatives and Biotechnology (Hemobrás) is advancing new investments and international partnerships to expand domestic production of blood-derived medicines, amid renewed debate over plasma regulation and the role of the state in the sector. A recent agreement with China’s Tiantan includes technology transfer and aims to increase Brazil’s industrial capacity…
PHARMABR WEEKLY
Get weekly insights from Brazil’s health sector
